Literature DB >> 9878616

Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein.

J E Crowe1, C Y Firestone, R Crim, J A Beeler, K L Coelingh, C F Barbas, D R Burton, R M Chanock, B R Murphy.   

Abstract

A recombinant human antibody fragment, designated RSV Fab 19, efficiently neutralizes respiratory syncytial virus (RSV). Here we report the results of our sequence analysis of antibody escape mutants that identified F glycoprotein amino acids critical for binding of human or murine RSV F-neutralizing antibodies. Copyright 1998 Academic Press.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9878616     DOI： 10.1006/viro.1998.9462

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  25 in total

Review 1.  Genetic and structural determinants of virus neutralizing antibodies.

Authors:  J E Crowe; R O Suara; S Brock; N Kallewaard; F House; J H Weitkamp
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Development of a luciferase immunoprecipitation system assay to detect IgG antibodies against human respiratory syncytial virus nucleoprotein.

Authors:  Sangeeta Kumari; Roberta Lynne Crim; Ashwin Kulkarni; Susette A Audet; Thembi Mdluli; Haruhiko Murata; Judy A Beeler
Journal:  Clin Vaccine Immunol       Date:  2014-01-08

3.  Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.

Authors:  Jarrod J Mousa; Marion F Sauer; Alexander M Sevy; Jessica A Finn; John T Bates; Gabriela Alvarado; Hannah G King; Leah B Loerinc; Rachel H Fong; Benjamin J Doranz; Bruno E Correia; Oleksandr Kalyuzhniy; Xiaolin Wen; Theodore S Jardetzky; William R Schief; Melanie D Ohi; Jens Meiler; James E Crowe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

4.  In vivo selection of respiratory syncytial viruses resistant to palivizumab.

Authors:  Xiaodong Zhao; Wayne M Sullender
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Gold nanorod vaccine for respiratory syncytial virus.

Authors:  John W Stone; Natalie J Thornburg; David L Blum; Sam J Kuhn; David W Wright; James E Crowe
Journal:  Nanotechnology       Date:  2013-06-25       Impact factor: 3.874

Review 6.  Neutralizing epitopes of RSV and palivizumab resistance in Japan.

Authors:  Koichi Hashimoto; Mitsuaki Hosoya
Journal:  Fukushima J Med Sci       Date:  2017-09-01

Review 7.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

8.  Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency.

Authors:  John T Bates; Christopher J Keefer; Thomas J Utley; Bruno E Correia; William R Schief; James E Crowe
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

9.  Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.

Authors:  José A Melero; Martin L Moore
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

10.  Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years.

Authors:  Chin-Fen Yang; Chiaoyin K Wang; Sharon J Tollefson; Rohith Piyaratna; Linda D Lintao; Marla Chu; Alexis Liem; Mary Mark; Richard R Spaete; James E Crowe; John V Williams
Journal:  Virol J       Date:  2009-09-09       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.